Gary Crocker, Chairman
James Dresser
Gordon Fehr
Robert Gay , Ph.D.
Peter Lewis
Walter Lovenberg, Ph.D.
Sarah Nash
Anthony Sinskey, Sc.D.
Robert Mulroy, President & CEO

Gary Crocker initially invested in Merrimack and joined the Board in 2004, and was elected as Chairman in the spring of 2005. Mr. Crocker is President of Crocker Ventures, LLC, a life science private investment firm. He is in the midst of his second term on the Board of Directors of the Federal Reserve Branch of San Francisco and also serves as a member of the Advisory Board of Sorenson Capital, an LBO private equity fund. He has held senior executive or director level positions in several successful life science firms including service from 1998 to 2003 as Chairman of ARUP Laboratories, as a director of Interleuken Genetics, Inc, and LineaGen Genetics, LLC., and as a co-founder and director of Theratech, Inc. which was acquired in 1999 by Watson Pharmaceuticals. From 1983 to 1997, he was President/CEO and founder of Research Medical, Inc., a publicly traded cardiac device manufacturer acquired by Baxter International in 1997. Prior to Research Medical, Mr. Crocker was Vice President, Business Development and Director of Marketing for the Sorenson Research division of Abbott Laboratories, and an Internal Strategic Analyst for Baxter International. He was recently inducted into the University of Utah Science Hall of Fame, and serves as a director of the University's Research Foundation. Mr. Crocker earned both his MBA and also graduated magna cum laude with a Bachelor of Science degree in Economics from Harvard University.

[ back to top ]

James Dresser joined the Board of Directors in 1998.  From 1970 until his retirement in 1997, Mr. Dresser held consulting and leadership positions at The Boston Consulting Group, where he served as the firm's first Chief Administrative Officer.  Mr. Dresser holds a MBA with High Distinction from Harvard, a MA from the Fletcher School of Law and Diplomacy, and a BA with Honors and Distinction from Wesleyan University .  After college, he served as a captain in Air Force Intelligence in Japan and Vietnam for four years.  Mr. Dresser recently retired as Chairman of the Board of Trustees of Wesleyan University. 

[ back to top ]

Gordon Fehr has served on the Board of Directors since the founding of the Company. Following 6 years in the oil industry with Shell and British Petroleum, Mr. Fehr joined Pfizer Canada, Inc. in 1963 and was named Chairman and President in 1972, a position he held until his retirement in 1994. A former President and Chairman of the Montreal Board of Trade, Mr. Fehr sits on the Board of the Research Institute of McGill University Health Centers where he Chairs the Audit and Investment Committees. Previously he was a Board Member of the Montreal Airport Authority and Labopharm, Inc. Mr. Fehr has served on a number of Advisory Boards including the National Research Council’s Biotechnology Research Institute and the Montreal Center of Innovative Technology where he Chaired the Biotechnology Committee. Mr. Fehr holds a degree in Chemical Engineering from McGill University

[ back to top ]

Robert Gay, Ph.D. joined the Board of Directors in 2007. Dr. Gay is a former Managing Director and Chairman of the Management Committee of Bain Capital. Bain Capital is one of the world’s leading private equity firms with over $40 billion in capital with offices in the US, Asia and Europe. Before joining Bain Capital, Dr. Gay was an Executive Vice President of General Electric Credit Corporation Capital Markets Group, Vice President in the Merchant Banking Group at Kidder Peabody, and Engagement Manager at the international consulting firm, McKinsey & Company. Dr. Gay received his undergraduate degree from the University of Utah and taught economics at Harvard University where he also received a PhD in Business Economics and the Harvard Business School Division of Research Scholarship.

[ back to top ]

Peter Lewis joined the Board of Directors in 2001. He is a founder and President of Wharton Equity Partners, LLC, a New York City-based holding company focused on real estate, private equity and venture capital investments. Since its formation in 1987, Wharton Equity has been involved in a wide array of real estate transactions as well as investments the life sciences, electronics manufacturing and energy industries.  Mr. Lewis received a BS in Economics from the Wharton School at the University of Pennsylvania and his MBA from the Graduate School of Business at Columbia University.

[ back to top ]

Walter Lovenberg, Ph.D. has been a director of the company since 2000. He is currently President of Lovenberg Associates, Inc. and Acting CEO and director of QuantumBio, Inc. He was a director of OSI Pharmaceuticals Inc. (1993-2006) and former director of several private biotechnology companies. Some of Dr. Lovenberg’s past positions include Executive Vice President and Board member of Marion Merrell Dow, Inc. where he was responsible for global research. He was previously Chief of the section of Biochemical Pharmacology at the National Institutes of Health in the U.S. Dr. Lovenberg received a Ph. D. from George Washington University and is author or coauthor of over 300 scientific publications. 

[ back to top ]

Sarah Nash joined the Board of Directors in 2006. Ms. Nash retired in 2005 as a Vice Chairman of JPMorgan Chase & Co.'s Investment Bank where she was responsible for the firm's client relationships. Prior to these responsibilities, she was the Regional Executive and Co-Head of Investment Banking for North America at J.P. Morgan & Co. Her personal areas of expertise are strategic advisory, capital raising and financial restructurings. Ms. Nash also serves on the board of Knoll Inc. where she serves on the Compensation and Audit Committees. Ms. Nash’s philanthropic leadership responsibilities include her serving as a Trustee for New York-Presbyterian Hospital where she serves on the Executive and Finance Committees and is Chair of the Investment Committee. Ms. Nash is a Trustee of Washington and Lee University and her other board positions include The New-York Historical Society, The New York Restoration Project and the Business Leadership Council of CUNY. Ms. Nash holds a bachelor’s degree from Vassar College.

[ back to top ]

Anthony Sinskey, Sc.D. is a co-founder of Merrimack and has served on the Board of Directors since 1998. Dr. Sinskey is a Professor of Microbiology in the Department of Biology at MIT. He is widely recognized for pioneering multidisciplinary approaches to metabolic engineering of biodegradable polymers, natural products (amino acids, antibiotics), and energy dense fuels. Dr. Sinskey has helped to found many successful biotechnology companies including Genzyme and Aspen Technology. Dr. Sinskey is a co-founder and member of the Board of Directors at Metabolix and Tepha and a consultant to several fine chemical and biotechnology companies. Dr. Sinskey received a Sc.D. from MIT in 1966.

[ back to top ]

Robert Mulroy, President & CEO of Merrimack, has been a Director since 1998. Click here to read his full bio.

[ back to top ]